These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 23399692)

  • 1. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.
    van Schouwenburg PA; Rispens T; Wolbink GJ
    Nat Rev Rheumatol; 2013 Mar; 9(3):164-72. PubMed ID: 23399692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors.
    Hernández-Breijo B; Navarro-Compán V; Plasencia-Rodríguez C; Parodis I; Gehin JE; Martínez-Feito A; Novella-Navarro M; Mezcua A; Warren DJ; Nozal P; Pascual-Salcedo D; Balsa A
    Sci Rep; 2021 Jun; 11(1):11632. PubMed ID: 34079038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what's in it for African and Middle Eastern rheumatologists.
    Alawadhi A; Alawneh K; Alzahrani ZA
    Clin Rheumatol; 2012 Sep; 31(9):1281-7. PubMed ID: 22875700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.
    Balsa A; Sanmarti R; Rosas J; Martin V; Cabez A; Gómez S; Montoro M
    Rheumatology (Oxford); 2018 Apr; 57(4):688-693. PubMed ID: 29365183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. The best practice for TNF inhibitors.].
    Kameda H
    Clin Calcium; 2018; 28(5):655-660. PubMed ID: 29731461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF α Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients.
    Arstikyte I; Kapleryte G; Butrimiene I; Venalis A
    Biomed Res Int; 2015; 2015():604872. PubMed ID: 26064930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation.
    Berkhout LC; Vogelzang EH; Hart MM; Loeff FC; Dijk L; Derksen NIL; Wieringa R; van Leeuwen WA; Krieckaert CLM; de Vries A; Nurmohamed MT; Wolbink GJ; Rispens T
    Clin Exp Rheumatol; 2020; 38(2):306-313. PubMed ID: 31498069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF in rheumatoid arthritis: an overview.
    Radner H; Aletaha D
    Wien Med Wochenschr; 2015 Jan; 165(1-2):3-9. PubMed ID: 25651945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis.
    Mok CC; Tsai WC; Chen DY; Wei JC
    Expert Opin Biol Ther; 2016; 16(2):201-11. PubMed ID: 26560845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission and low disease activity matrix tools: results in real-world rheumatoid arthritis patients under anti-TNF therapy.
    Ganhão S; Lucas R; Fonseca JE; Santos MJ; Gonçalves DR; Madeira N; Silva C; Dourado E; Freitas R; Rodrigues J; Azevedo S; Rocha TM; Ferreira RM; Garcia S; Fernandes BM; Prata AR; Couto M; Torres RP; Cunha I; Costa L; Bernardes M
    Acta Reumatol Port; 2020; 45(4):245-252. PubMed ID: 33420771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
    Aaltonen KJ; Virkki LM; Malmivaara A; Konttinen YT; Nordström DC; Blom M
    PLoS One; 2012; 7(1):e30275. PubMed ID: 22272322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of TNF-Inhibitors.
    Atiqi S; Hooijberg F; Loeff FC; Rispens T; Wolbink GJ
    Front Immunol; 2020; 11():312. PubMed ID: 32174918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of anti-nuclear antibodies is a risk factor for the appearance of anti-drug antibodies during infliximab or adalimumab therapy in patients with rheumatoid arthritis.
    Mori A; Saito T; Takahashi M; Shibata M; Tsuji G; Hatachi S; Takahashi S; Kumagai S
    PLoS One; 2020; 15(12):e0243729. PubMed ID: 33315881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
    Bourne T; Fossati G; Nesbitt A
    BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Percentage of Signal Regulatory Protein α/β
    Magill L; Adriani M; Berthou V; Chen K; Gleizes A; Hacein-Bey-Abina S; Hincelin-Mery A; Mariette X; Pallardy M; Spindeldreher S; Szely N; Isenberg DA; Manson JJ; Jury EC; Mauri C
    Front Immunol; 2018; 9():2865. PubMed ID: 30568660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.